Matthias Eder
Eder, Matthias
Prof. Dr. sc. hum.
Division of Radiopharmaceutical Development, Department of Nuclear Medicine, University Medical Center,
Hugstetter Straße 55, D-79106 Freiburg
matthias.eder[a]uniklinik-freiburg.de
Current position
Full Professor (W3) of Radiopharmaceutical Development, Department of Nuclear Medicine,
University Medical Center, Freiburg;
Head of Division of Radiopharmaceutical Development, DKTK Freiburg, German Cancer Research Center, Heidelberg
Research topic in GRK 2606: Substrate-like protease probes
University training and degree(s)
2001-2005 Study of Biotechnology, University of Applied Sciences, Mannheim
Advanced academic qualifications
2009 Dissertation in Radiopharmacy, German Cancer Research Center Heidelberg
Postgraduate Positions
Since 2017 Full Professor (W3) of Radiopharmaceutical Development, Department of
Nuclear Medicine, University Medical Center, Freiburg
Since 2017 Head of Division Radiopharmaceutical Development, DKTK Freiburg, German
Cancer Research Center, Heidelberg
2015-2017 Research Group in the Clinical Cooperation Unit Nuclear Medicine,
German Cancer Research Center and University Hospital, Heidelberg
2013-2015 Group Leader; “Radiopharmaceutical Sciences”, Division of
Radiopharmaceutical Chemistry, German Cancer Research Center,
Heidelberg
2009-2013 Postdoc; Division Radiopharmaceutical Chemistry, German Cancer Research
Center, Heidelberg
Other
2012 Dr. Emil Salzer Prize for Cancer Research
2014 EANM Springer Prize 2014 for the Best Clinical Paper
2015 International Best Abstracts Award, SNMMI annual meeting
2015 Berson-Yalow Award, Society of Nuclear Medicine
2015 Image of the Year Award, Society of Nuclear Medicine
2015 EANM Eckert & Ziegler Abstract Award 2015
2015 EANM Springer Prize · Best Paper 2015
2016 EANM Springer Prize · Best Paper 2016
2017 Image of the Year Award, Society of Nuclear Medicine
2017 EANM Springer Prize · Most cited paper 2017 - European Journal of Nuclear
2017 EANM Springer Prize · Best Paper 2017- European Journal of Nuclear Medicine and Molecular
2018 Erwin Schrödinger-Prize 2018, Helmholtz Association of German Research Centres
10 important publications
- Eder, M., Knackmuss, S., Le Gall, F., Reusch, U., Rybin, V., Little, M., Haberkorn, U., Mier, W., and Eisenhut, M. (2010). (68)Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. Eur. J. Nucl. Med. Mol. Imaging 37, 1397-407.
- Eder, M., Schafer, M., Bauder-Wust, U., Hull, W. E., Wangler, C., Mier, W., Haberkorn, U., and Eisenhut, M. (2012). (68)Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. Bioconjug. Chem. 23, 688-97.
- Eder, M., Lohr, T., Bauder-Wust, U., Reber, M., Mier, W., Schafer, M., Haberkorn, U., and Eisenhut, M. (2013). Pharmacokinetic Properties of Peptidic Radiopharmaceuticals: Reduced Uptake of (EH)3-Conjugates in Important Organs. J. Nucl. Med. 54, 1-4.
- Eder, M., Eisenhut, M., Babich, J., and Haberkorn, U. (2013). PSMA as a target for radiolabelled small molecules. Eur. J. Nucl. Med. Mol. Imaging 40, 819-23.
- Haberkorn, U., Eder, M., Kopka, K., Babich, J. W., and Eisenhut, M. (2016). New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. Clin. Cancer Res. 22, 9-15.
- Kratochwil, C., Giesel, F. L., Stefanova, M., Benesova, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., and Haberkorn, U. (2016). PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. J. Nucl. Med. 57, 1170-6.
- Benesova, M., Schafer, M., Bauder-Wust, U., Afshar-Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, K., and Eder, M. (2015) Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J. Nucl. Med. 56, 914-20.
- Benesova, M., Bauder-Wust, U., Schafer, M., Klika, K. D., Mier, W., Haberkorn, U., Kopka, K., and Eder, M. (2016). Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. J. Med. Chem. 59, 1761-75.
- Baranski, A. C., Schafer, M., Bauder-Wust, U., Wacker, A., Schmidt, J., Liolios, C., Mier, W., Haberkorn, U., Eisenhut, M., Kopka, K., and Eder, M. (2017). Improving the Imaging Contrast of (68)Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties. Bioconjug. Chem. 28, 2485-2492.
- Eder, M., S. Pavan, U. Bauder-Wust, K. van Rietschoten, A. C. Baranski, H. Harrison, S. Campbell, C. L. Stace, E. H. Walker, L. Chen, G. Bennett, G. Mudd, U. Schierbaum, K. Leotta, U. Haberkorn, K. Kopka and D. P. Teufel (2019). Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors. Cancer Res. 79, 841-852.